Enovis CEO Matt Trerotola to retire, board seeks replacement

Enovis (ENOV) announced that Matt Trerotola has informed the Board of Directors of his intention to retire from his position as CEO, effective upon his successor being appointed by the Board and assuming the position as CEO. As part of the company’s succession planning process, the Board is actively working with an executive search firm to identify a growth-oriented MedTech leader who shares a passion for continuous improvement and patient outcomes, to serve as the company’s next CEO. Upon the appointment of his successor, to facilitate a smooth leadership transition, Enovis and Trerotola will enter into a retirement and transition agreement, pursuant to which Trerotola has agreed to continue to serve as an employee and an Executive Advisor to the company and his successor for a period of one year from the date of such appointment.